[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rabies-healthy-volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rabies-healthy-volunteers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,76,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100627952","phase-3-boostability-assessment-of-three-rabies-pre-exposure-regimens-in-healthy-volunteers-5-years-following-priming-100627952",false,"NCT07455318","Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.","A Multicentre, Open-label Trial in Healthy Volunteers to Assess the Boostability of Three Different Rabies Pre-exposure Prophylaxis Regimens When Administering a Single-dose, Intramuscular Vaccination as Simulated Post-exposure Prophylaxis at Least Five Years Following Priming.","BAZOOKA_221","Inclusion Criteria:\n\n1. ≥ 18 to ≤ 60 years of age at time of inclusion\n2. Willingness to provide written informed consent\n3. Having received PrEP with a 21IM, 2²ID or 1²ID regimen at least 5 years before starting the study. For 21IM and 2²ID interval of 5 days to 56 days between the 2 visits is allowed.\n\nExclusion Criteria:\n\n1. Known allergy to one of the components of the vaccine.\n2. Subjects, who received immunomodulating therapy within the last 3 months (12 weeks).\n\n   Note: See Section 6.3 for detailed guidance on immunomodulating therapies.\n3. Planned vaccination with any inactivated vaccine within 2 weeks before or after vaccination in the study or with any live attenuated vaccine within 1 month before or after each vaccination in the study.\n4. Ongoing pregnancy or active child wish at the time of booster vaccination (D0).\n5. Any other PrEP rabies vaccine schedule\u002Fvaccination than mentioned in the inclusion criteria.\n6. Previous rabies (s)PEP\n7. Inability or unwillingness to comply with study procedures, including protocol-defined visits, assessments, or interventions.","ALL","18 Years","60 Years",{"count":21,"type":22},561,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A multicentre, open label trial in healthy volunteers to assess the boostability of three different rabies pre-exposure prophylaxis regimens (2 x 1IM regimen, 2 x 2 ID regimen, 1 x 2 ID regimen) when administering a single-dose, intramuscular vaccination as simulated post-exposure prophylaxis at least five years following priming.",[28],"Rabies (Healthy Volunteers)",[30,31,32,33,34,35],"Rabies","Vaccination regimens","rabies pre-exposure prophylaxis","boostability","prophylaxis","vaccination","NOT_YET_RECRUITING","2026-03-02",{"date":39,"type":40},"2026-03-06","ACTUAL",{"date":42,"type":22},"2026-05-15",{"date":44,"type":22},"2027-06",{"name":46,"class":47},"Institute of Tropical Medicine, Belgium","OTHER",6,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":54,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100627221","phase-2-a-phase-ii-trial-of-a-recombinant-human-anti-rabies-virus-monoclonal-antibody-100627221","NCT07445815","A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy individuals aged 18-60 years (inclusive), regardless of gender, capable of providing valid legal identification.\n2. Participants voluntarily agree to participate in the study and sign an informed consent form.\n3. Female participants must have no plans for pregnancy or egg donation from 14 days prior to dosing until 6 months after dosing and must voluntarily adopt effective physical contraceptive measures. Male participants must have no plans for pregnancy or sperm donation within 6 months after dosing and must voluntarily adopt effective physical contraceptive measures.\n4. Female participants must weigh ≥45.0 kg and ≤80.0 kg, and male participants must weigh ≥50.0 kg and ≤80.0 kg. Body mass index (BMI) must be between 18.0 and 26.0 kg\u002Fm² (inclusive) (BMI = weight in kg \u002F height in m²).\n5. Vital signs (reference ranges: systolic blood pressure 90-140 mmHg, diastolic blood pressure 60-90 mmHg, pulse rate 50-100 beats per minute, all inclusive; body temperature assessed by the investigator according to the research center's standards), physical examination, and clinical laboratory and auxiliary tests during the screening period must be normal or judged by the investigator to have no clinical significance if abnormal.\n\nExclusion Criteria:\n\n1. Known allergy to the investigational product (including excipients or similar drugs), or individuals with a history of severe allergic diseases or considered allergic constitution (e.g., allergies to two or more drugs, foods, or pollen) as judged by the investigator to potentially compromise participant safety.\n2. Clear history of allergy to essential substances that may be encountered during the trial (e.g., skin disinfectants).\n3. History of clinically severe diseases within the 6 months (180 days) prior to screening that remain unresolved, or current acute or chronic illnesses that may significantly affect the metabolism or safety evaluation of the investigational product.\n4. History of autoimmune diseases or chronic hepatitis.\n5. History of seizures, epilepsy, psychiatric or neurological disorders, or family history of seizures or epilepsy.\n6. Major surgery within the 3 months (90 days) prior to screening, or surgery that may significantly affect the metabolism or safety evaluation of the investigational product.\n7. Previous vaccination with human rabies vaccine, or suspected history of rabies exposure (defined as bites, scratches, licks on mucous membranes or broken skin by rabid, suspected rabid, or undetermined rabies status animals, or direct contact of open wounds or mucous membranes with saliva or tissues potentially containing rabies virus), as determined by inquiry.\n8. Positive screening for anti-rabies virus antibodies during the screening period.\n9. Vaccination with any vaccine other than the rabies vaccine within the 1 month (30 days) prior to screening.\n10. Use of other antibody-based drugs or immunoglobulins within the 3 months (90 days) prior to screening.\n11. Use of passive immunizing agents, immunosuppressants, or corticosteroids within the 3 months (90 days) prior to screening.\n12. Use of medications that may affect the metabolism or safety evaluation of the investigational product within the 14 days prior to screening or ongoing use of such medications.\n13. Participation in any clinical trial involving the use of investigational drugs or devices within the 3 months (90 days) prior to screening, or planned participation in other clinical trials during this study.\n14. Regular alcohol consumption within the 3 months (90 days) prior to screening, averaging more than 2 alcohol units per day (1 unit = 17.7 mL ethanol, equivalent to 357 mL of 5% beer, 43 mL of 40% spirits, or 147 mL of 12% wine), or inability to abstain from alcohol during the trial period.\n15. Smoking habit within the 3 months (90 days) prior to screening (more than 5 cigarettes or equivalent tobacco per day), or inability to abstain from smoking during the trial period.\n16. Blood loss\u002Fdonation exceeding 300 mL (excluding physiological blood loss in females) within the 3 months (90 days) prior to screening, receipt of blood transfusions or blood products, or plans to donate blood within 1 month (30 days) after the trial.\n17. Inability to avoid strenuous exercise within 14 days after dosing.\n18. History of drug abuse.\n19. Pregnant or breastfeeding women.\n20. History of needle or blood phobia, poor vascular condition, or intolerance to venipuncture.\n21. Participants who may be unable to cooperate in completing the study for other reasons or are deemed unsuitable for inclusion by the investigator.",true,{"count":58,"type":22},200,[60],"PHASE2",[28],[63,30,64],"Recombinant Human","Monoclonal Antibody","2026-02-25",{"date":67,"type":40},"2026-03-03",{"date":69,"type":22},"2026-01-31",{"date":71,"type":22},"2026-08-21",{"name":73,"class":74},"Lanzhou Institute of Biological Products Co., Ltd","INDUSTRY",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100624936","phase-3-phase-iiib-clinical-trial-to-evaluate-lot-to-lot-consistency-of-sinovac-rabies-vaccine-100624936","NCT07416110","Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine","Lot-to-lot Consistency and Safety of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried in Healthy Individuals Aged 18-45 Years: A Randomized, Double-Blind Phase IIIb Clinical Trial","Inclusion Criteria:\n\n1. Participants are able to understand and voluntarily sign the Informed Consent Form;\n2. Able to provide legal identity documents;\n3. Age 18 to 45 years;\n4. Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in original treatment or hospitalization due to disorder aggravation);\n5. Female participants of childbearing potential must voluntarily adopt effective contraception measures from the signing of the Informed Consent Form until 2 months after the last dose of the investigational Vaccine in the primary immunization series, and have no plans to donate eggs; male participants have no plans to donate sperm; female participants of childbearing potential must also have adopted effective contraception measures within 2 weeks prior to Enrollment.\n\nExclusion Criteria:\n\n1. For subjects with pyrexia on the scheduled vaccination day, axillary temperature \\>37.3℃ before vaccination;\n2. Previous use of anti-Rabies Passive immunization preparations (including but not limited to equine-derived Immunoglobulin ERIG, human-derived Immunoglobulins HRIG, and rabies monoclonal antibody preparations, etc.) or previous Vaccination with human Rabies Vaccine;\n3. Individuals with mammalian animal bites\u002Fscratches (e.g., dog\u002Fcat) and broken skin (i.e., Category II or higher exposure) within the past year.;\n4. Female participants who are lactating or pregnant (including those with a positive urine pregnancy test).\n5. Known allergy to any component of the trial Vaccine, or a history of severe allergies (such as anaphylactic shock, allergic laryngeal edema, allergic purpura, severe urticarial rash, dyspnea, angioneurotic edema, etc.);\n6. Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, asplenia, functional asplenia, splenectomy);\n7. Poorly controlled chronic diseases or history of severe diseases, including but not limited to cardiovascular disorders (e.g., uncontrolled hypertension: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), metabolic diseases (e.g., poorly controlled diabetes), hematological diseases, liver and kidney diseases, digestive system diseases, respiratory system disorders, history of major organ transplantation, malignant neoplasms within the past five years, or any other diseases or physiological conditions that the investigator believes may interfere with the trial results.\n8. History of encephalopathy with significant recovered with sequelae or dysfunction, or current encephalopathy (e.g., congenital cerebral dysgenesis, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarct, brain infection, chemical drug poisoning, etc., causing brain nerve tissue injury); history of convulsions, epilepsy, mental illness or family history of mental illness, or other serious neurological diseases;\n9. Presence of physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiency, coagulation disorders, platelet abnormalities);\n10. Systemic immunosuppressive agents or other immunomodulatory therapy for ≥14 days within the past 6 months (prednisone ≥20 mg\u002Fday or ≥2 mg\u002F(kg·day), or equivalent), cytotoxic therapy, or planned receipt of such therapy during the study period;\n11. Received Immunoglobulins or other blood products within 3 months prior to receiving the investigational Vaccine, or plans to receive such treatment during the study period;\n12. Received other Study Drug or Vaccine within the past 30 days, or plans to receive such drug or Vaccine during the study period;\n13. Within 14 days prior to receiving the investigational vaccine, vaccination with a live attenuated vaccine, or within 7 days, vaccination with subunit, inactivated, or other types of vaccines.\n14. Currently participating in other Vaccine or drug Clinical Studies, or planning to participate in other Clinical Trials during the study period;\n15. Subjects with skin injuries, inflammation, ulcers, skin rash, or scars at the Vaccination site that may interfere with dosing or the observation of local reactions.\n16. Within 3 days prior to vaccination, any acute disease or acute exacerbation of a chronic disease, or known or suspected active infection;\n17. Based on the Investigator's judgment, the participant has any other discomfort or factors suitable for participating in the clinical trial.","45 Years",{"count":85,"type":22},912,[25],"To evaluate immunogenicity consistency between three consecutive batches of commercial-scale productions for Sinovac Rabies vaccine",[28],[90,91,92],"rabies vaccine","serum-free","lot-to-lot consistency","2026-02-10",{"date":95,"type":40},"2026-02-17",{"date":97,"type":22},"2026-03-04",{"date":99,"type":22},"2027-06-30",{"name":101,"class":74},"Sinovac Biotech Co., Ltd",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":56,"sex":17,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":75},"100597238","phase-3-immunogenicity-and-safety-of-rabies-vaccine-serum-free-vero-cell-in-a-simulated-post-exposure-prophylaxis-regimen-100597238","NCT07055893","Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen","Immunogenicity and Safety of a Rabies Vaccine (Serum-free Vero Cell), Freeze-dried in Comparison With Verorab®, in a Simulated Post-exposure Prophylaxis Regimen in Healthy Populations Aged ≥1 Years: A Randomized, Double-Blind, Active-controlled Phase Ⅲ Clinical Trial","Inclusion Criteria:\n\n1. Populations aged ≥1 years old;\n2. Participants and\u002For participants' parents\u002Flegal guardians are able to understand and sign the informed consent form (ICF) voluntarily;\n3. Participants are able to comply with the study procedures based on the investigator's assessment;\n4. In a stable health status (defined as a stable preexisting disease status during the past 3 months, i.e., no change in treatment or hospitalization due to exacerbation of preexisting diseases);\n5. Participants were tested negative for HIV, Syphilis, Hepatitis B, Hepatitis C infection at the screening of this study (the test result should be provided);\n6. Female participants aged ≥15 years old with childbearing potential were tested negative for urine pregnancy test pre-vaccination, and also need to have effective contraceptive measures in the previous 2 weeks pre-vaccination.\n7. Participants of childbearing potential and their partners are willing to take effective contraceptive measures and have no sperm or ovum donation plan from the time of signing ICF to 28 days after the last dose of vaccination;\n8. Participants should provide verifiable identifications, and contact or be contacted with the investigators during the study period\n\nExclusion Criteria:\n\n1. Fever on vaccination day, with axillary temperature \\>37.0°C (aged ≥5 years old) or \\>37.3°C (aged 1\\~4 years old) pre-vaccination;\n2. Previous vaccination against rabies (in pre- or post-exposure regimen) with either trial vaccines or licensed vaccines;\n3. Previous administration with rabies immunoglobulins or monoclonal antibodies;\n4. Bite by, or exposure to a potentially rabid animal in the previous 12 months with category Ⅱ or Ⅲ exposures;\n5. Female participants who are currently lactating or pregnant;\n6. Known serious allergy to vaccines or vaccine ingredients, such as severe urticaria, anaphylactic shock, allergic laryngeal edema, allergic purpura, or known other serious adverse reactions to vaccine;\n7. With severe congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n8. With autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection);\n9. With poor controlled chronic illnesses or history of severe diseases, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, a history of major organ transplantation, drug-uncontrolled hypertension (only for participants aged ≥18 years old: with systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg), or any other disease or medical condition that the investigator believes could interfere with the trial results;\n10. With current or past history of severe neurological diseases (epilepsy, convulsions or seizures \\[excluding history of febrile seizures\\]) or psychiatric disorders, or presence of a family history of psychiatric disorders;\n11. With coagulation disorders (eg. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture;\n12. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment in this study;\n13. With long-term alcohol abuse \\[\\>14 drinks per week (1 drink =14 g 100% alcohol =360 mL beer, or 150 mL wine, or 45 mL distilled liquor\u002Fliquor)\\] or substance abuse (repeated and heavy use of narcotic drugs, psychotropic drugs, volatile organic solvents, etc.)\n14. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the study;\n15. Receipt of other investigational drugs\u002Fvaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period;\n16. Currently participating in other vaccine or drug clinical trials, or plan to participate in other clinical trials during the study;\n17. Receipt of live-attenuated vaccines within 14 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening;\n18. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended vaccination site that may interfere with drug administration or observation of local reactions;\n19. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections;\n20. Any other factors considered by the investigator to make the participant unsuitable for participation in the study","1 Year",{"count":112,"type":22},390,[25],"To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the pediatric and adult population in a PEP schedule",[28],[90,117,118],"Serum-free","post-exposure prophylaxis","2025-06-27",{"date":121,"type":40},"2025-07-09",{"date":123,"type":22},"2026-03-01",{"date":125,"type":22},"2027-01-30",{"name":101,"class":74}]